Koninklijke Philips N.v. · EURONEXT:PHIA
Koninklijke Philips — Koninklijke Philips N.V. NY Registry Shares — Q1 2026 Earnings Presentation
27 slides from Koninklijke Philips's earnings presentation, May 6, 2026
Slide 1: First quarter 2026 results
First quarter 2026 results Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer PHILIPS
Slide 2: Table of contents
Table of contents First quarter 2026 performance 4 2026 outlook 17 Financial appendix 22 © 2024 Koninklijke Philips LV. A rights reserved PHILIPS
Slide 3: Important information
Important information Forward-looking statements and other important information This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and
Slide 4: Key takeaways
Key takeaways Q1 highlights * Order intake increased 6%, driven by growth in both Diagnosis & Treatment and Connected Care, led by North America « Comparable sales grew 4%, with growth across all business segments, led by Personal Health « Adjusted EBITA margin increased 40 bps to 9.0%, driven by sa
Slide 5: Sustained order intake growth and a solid order book support acceleration of profitable growth in 2026
Sustained order intake growth and a solid order book support acceleration of profitable growth in 2026 Comparable equipment order intake growth’ Indexed equipment order book' development 12% 10% 8% 7% 6% 6% 4% 2% === In the quarter === Rolling last twelve months 0% Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1
Slide 6: Rembra Wide-bore, Spectral Verida, SmartHeart
Rembra Wide-bore Spectral Verida Largest-in-class 85 cm World's first bore accommodates Al-powered detector-based diverse patient needs and spectral CT supports complex interventions 1. FDA 510(k) cleared in the USA and CE marked in Europe; data on file at Philips. When compared to IntraSight, SyncV
Slide 7: New 5700-7300 Series and Sonicare 7000
New 5700-7300 Series With its Next-Generation Sonicare technology including a re-engineered motor and adaptive magnetic system that deliver up to 62,000 consistent bristle movements per minute Sonicare 7000 Launched at the South China Dental Show, reinforcing momentum in professional oral care
Slide 8: Diagnosis & Treatment
In millions of unless o Sales 1,848 1,965 Comparable sales growth 2% -4% Adj. EBITA margin 9.8% 9.5% Income from operations 194 153 ¢ High-single-digit growth in Image Guided Therapy partly offset by a low-single-digit decline in Precision Diagnosis * Growth led by North America and Europe, partly o
Slide 9: Leading the transition to helium-free operations in MR with BlueSeal
Leading the transition to ; helium-free operations in MR with BlueSeal Resilience in MRI now matters as much as performance ee: and nr Middle East Puerto Rico , Impact on global Restored operations P ortugal helium supply and rapidly after major. Demonstrated pricing; BlueSeal infrastructure resilie
Slide 10: Spectral CT Verida
10 Spectral CT Verida Initial orders secured in Europe ia ae Industry’s first Al-enabled detector-based spectral CT First clinical installation in Madrid in Q1 2026 “The Verida Spectral CT allows us to naturally integrate spectral imaging into our daily work without disrupting the reading workflow o
Slide 11: Connected Care
Sales 1,062 1,182 Comparable sales growth 3% 0% Adj. EBITA margin 2.9% 3.5% Income from operations -54 -81 « Mid-single-digit growth in Monitoring and low-single-digit growth in Sleep & Respiratory Care, partly offset by a low-single- digit decline in Enterprise Informatics * Growth led by Europe an
Slide 12: Personal Health
Personal Health Financial performance In millions of EUR Qi unless otherwise stated Sales 811 Comparable sales growth 1% Adj. EBITA margin 15.2% Income from operations 116 Q1 2026 highlights « All three businesses grew. Growth was broad-based, led by North America and the International Region, with
Slide 13: Growth, share gains, and momentum in Personal Health driven by category growth and channel expansion
B Growth, share gains, and momentum in Personal Health driven by category growth and channel expansion Increased distribution points Increased listing with key global retail partners k . Intense Pulsed Light + in Europe | Interdental PHILIPS
Slide 14: Solid start to the year in an uncertain macro-environment
14 Solid start to the year in an uncertain macro-environment; delivered strong order intake, comparable sales growth and margin expansion Q1 2026 vs Q1 2025 In millions of EUR unless otherwise stated Adjusted EBITA Free Cash Flow 3,905 353 28 aiaiay Ti Growth 9.0%, “740 bps Us eee a emer +94 « Growt
Slide 15: Adjusted EBITA margin expansion driven by sales growth, favorable mix effects and productivity measures
15 Adjusted EBITA margin expansion driven by sales growth, favorable mix effects and productivity measures, partly offset by tariffs and cost inflation Group Adj. EBITA margin’ Q1 2026 2.6% -3.2% ; 0.2% 0.8% Adj. EBITA Volume, business mix, Productivity, Cost inflation FX, other Adj. EBITA Q1 2025 i
Slide 16: Productivity initiatives delivered savings in Q1
Productivity initiatives delivered EUR 126 million deliver our EUR 1.5 billion program in 2028 Productivity initiatives savings’ in Q1; on track to In millions of EUR unless otherwise stated 2026-2028 Cost competitiveness Project Synchronize Lean enabling functions Simplify to Perform Tariff mitigat
Slide 17: 2026 outlook
2026 outlook PHILIPS
Slide 18: Philips reiterates its full-year 2026 outlook
Philips reiterates its full-year 2026 outlook Full-year 2026 + All business segments growing within the range: Diagnosis & Treatment at the lower end; Connected Care and Personal Health at the upper end Comparable sales growth * Growth led by North America and International Regions; Greater China sa
Slide 19: Restructuring, acquisition-related charges and other items
19 Restructuring, acquisition-related charges and other items Full-year 2026 Restructuring costs ~80 bps Other items ~120 bps Q2 2026 Restructuring costs, other items Cost competitiveness (Project Synchronize) Lean enabling functions (Simplify to Perform) Mainly related to the Consent Decree, other
Slide 20: Latest FX, below the line items and segment Other outlook
Latest FX, below the line items and segment Other outlook Q2 2026 Full year 2026 Diagnosis & Treatment -3% -2% Connected Care (including divestment of Emergency Care2) -10% -8% Personal Health 4% -2% Effectivetaxrate 2 Ce Segment Other(EURmilion) Sales ~160 650 - 6803 Adj. EBITA “5 ~0 EBITA ~-5 ~-70
Slide 21: Global hospital demand and consumer sentiment
a Global hospital demand and consumer sentiment Diagnosis & Treatment and Connected Care Key drivers Personal Health ©) North America _) Europe Strong Stable + Productivity Productivity and digitalization * Patient volume * Health system financial improvement Measured Strong _) Greater China Cautiou
Slide 22: Financial appendix
Financial appendix © Koninklijke Philips NV. PHILIPS
Slide 23: Working capital and inventories
Working capital and inventories Group working capital" Group inventories In millions of EUR unless otherwise stated as % of last twelve months sales? 18.6% In millions of EUR unless otherwise stated as % of last twelve months sales? 12.0% 11.9% 3,500 18.1% 18.3% 2500 9.5% 9.9% 17.6% 2,000 a — == ~-—
Slide 24: Debt maturity profile and liability management
Debt maturity profile and liability management Long-term debt profile and liability management Debt maturity profile as per March 31, 2026 in billions of EUR unless otherwise stated H Long-term debt" ¢ Total net debt position of EUR 5.5 billion 18 [Short-term debe Un-utilized standby and + Maturitie
Slide 25: Net capital expenditures, depreciation and amortization
Net capital expenditures, depreciation and amortization In millions of EUR unless otherwise stated Q12026 Q12025 Net capital expenditures -160 -158 Depreciation -148 -151 Amortization and impairment: -117 -125 of acquired intangible assets -50 -57 of other intangible assets -67 -68 25 Note: Amounts
Slide 26: Restructuring, acquisition-related charges and other items
26 Restructuring, acquisition-related charges and other items In millions of EUR unless otherwise stated Q1 2026 Restructuring and acquisition- related charges Diagnosis & Treatment (34) Connected Care 23 Personal Health 2 Segment Other 30 Philips Group 22 Other items Diagnosis & Treatment 4 Connect
Slide 27: PHILIPS
PHILIPS
Koninklijke Philips N.V. NY Registry Shares — Q1 2026 Earnings Presentation on 6ix